The University of Chicago Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Daniel J. Haraf and Ralph R. Weichselbaum.
Daniel J. Haraf
Connection Strength
2.403
Ralph R. Weichselbaum
  1. Is It Worth It? Consequences of Definitive Head and Neck Reirradiation. Semin Radiat Oncol. 2020 Jul; 30(3):212-217.
    View in: PubMed
    Score: 0.185
  2. Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. Clin Cancer Res. 1996 Apr; 2(4):755-62.
    View in: PubMed
    Score: 0.138
  3. Photon neutron mixed-beam radiotherapy of locally advanced prostate cancer. Int J Radiat Oncol Biol Phys. 1995 Aug 30; 33(1):3-14.
    View in: PubMed
    Score: 0.132
  4. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012 Jun 01; 118(11):2962-70.
    View in: PubMed
    Score: 0.101
  5. Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer. Am J Clin Oncol. 1991 Oct; 14(5):419-26.
    View in: PubMed
    Score: 0.101
  6. Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol. 2010 Jan 01; 28(1):15-20.
    View in: PubMed
    Score: 0.089
  7. Treatment selection in T1 and T2 vocal cord carcinoma. Oncology (Williston Park). 1988 Oct; 2(10):41-50.
    View in: PubMed
    Score: 0.082
  8. An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res. 2008 Aug 15; 14(16):5255-9.
    View in: PubMed
    Score: 0.081
  9. Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions. Int J Oncol. 2006 May; 28(5):1141-51.
    View in: PubMed
    Score: 0.069
  10. Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. Int J Radiat Oncol Biol Phys. 2005 Mar 15; 61(4):1096-106.
    View in: PubMed
    Score: 0.064
  11. Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. Int J Oncol. 2004 Dec; 25(6):1677-83.
    View in: PubMed
    Score: 0.063
  12. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5936-43.
    View in: PubMed
    Score: 0.059
  13. Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. Ann Oncol. 2003 Apr; 14(4):564-9.
    View in: PubMed
    Score: 0.056
  14. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol. 2003 Jan 15; 21(2):320-6.
    View in: PubMed
    Score: 0.055
  15. Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer. Cancer J. 2001 Mar-Apr; 7(2):140-8.
    View in: PubMed
    Score: 0.048
  16. Sequential induction chemotherapy and concomitant chemoradiotherapy in the management of locoregionally advanced laryngeal cancer. Ann Oncol. 2001 Mar; 12(3):343-7.
    View in: PubMed
    Score: 0.048
  17. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol. 2000 Apr; 18(8):1652-61.
    View in: PubMed
    Score: 0.045
  18. Multimodality therapy in advanced paranasal sinus carcinoma: superior long-term results. Cancer J Sci Am. 1999 Jul-Aug; 5(4):219-23.
    View in: PubMed
    Score: 0.043
  19. Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer. Semin Radiat Oncol. 1999 Apr; 9(2 Suppl 1):70-6.
    View in: PubMed
    Score: 0.042
  20. Radiation therapy with concomitant hydroxyurea and fluorouracil in stage II and III head and neck cancer. J Clin Oncol. 1999 Feb; 17(2):638-44.
    View in: PubMed
    Score: 0.042
  21. Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer. Semin Oncol. 1997 Feb; 24(1 Suppl 2):S2-68-S2-71.
    View in: PubMed
    Score: 0.037
  22. Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease. Ann Oncol. 1996 Nov; 7(9):913-8.
    View in: PubMed
    Score: 0.036
  23. The role of paclitaxel in the treatment of head and neck cancer. Semin Oncol. 1995 Oct; 22(5 Suppl 12):8-12.
    View in: PubMed
    Score: 0.033
  24. Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil, and concomitant radiotherapy for poor-prognosis head and neck cancer. Semin Oncol. 1995 Jun; 22(3 Suppl 6):47-52.
    View in: PubMed
    Score: 0.033
  25. Cellular and molecular mechanisms of radioresistance. Cancer Treat Res. 1995; 74:131-40.
    View in: PubMed
    Score: 0.032
  26. Timing and sequencing of chemoradiotherapy. Cancer Treat Res. 1995; 74:173-98.
    View in: PubMed
    Score: 0.032
  27. Surgical management of the head and neck cancer patient following concomitant multimodality therapy. Laryngoscope. 1995 Jan; 105(1):97-101.
    View in: PubMed
    Score: 0.032
  28. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer. J Clin Oncol. 1994 Nov; 12(11):2351-9.
    View in: PubMed
    Score: 0.031
  29. Radiation therapy in head and neck cancer: indications and limitations. Semin Oncol. 1994 Jun; 21(3):296-303.
    View in: PubMed
    Score: 0.030
  30. Race and competing mortality in advanced head and neck cancer. Oral Oncol. 2014 Jan; 50(1):40-4.
    View in: PubMed
    Score: 0.029
  31. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res. 1993 Aug 15; 53(16):3667-9.
    View in: PubMed
    Score: 0.029
  32. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. Ann Oncol. 2013 Mar; 24(3):769-76.
    View in: PubMed
    Score: 0.027
  33. Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Cancer Res. 1992 Sep 01; 52(17):4832-6.
    View in: PubMed
    Score: 0.027
  34. Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor-prognosis head and neck cancer. Laryngoscope. 1992 Jun; 102(6):630-6.
    View in: PubMed
    Score: 0.026
  35. Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer. Semin Oncol. 1992 Jun; 19(3 Suppl 9):53-8.
    View in: PubMed
    Score: 0.026
  36. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol. 2012 Feb; 7(2):376-81.
    View in: PubMed
    Score: 0.026
  37. Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: a feasible and active approach. Ann Oncol. 1992 Jan; 3(1):79-81.
    View in: PubMed
    Score: 0.026
  38. 5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study. Cancer Chemother Pharmacol. 1992; 29(3):178-84.
    View in: PubMed
    Score: 0.026
  39. Radioresistant derivatives of radiosensitive CHO cells obtained following treatment with 5-azacytidine retain their sensitivity to cisplatin. Radiat Res. 1991 Aug; 127(2):226-9.
    View in: PubMed
    Score: 0.025
  40. Temporal bone chemodectomas--comparing surgery and radiation therapy. Oncology (Williston Park). 1991 Apr; 5(4):131-7; discussion 140, 143.
    View in: PubMed
    Score: 0.024
  41. Modeling of dose to tumor and normal tissue from intraperitoneal radioimmunotherapy with alpha and beta emitters. Int J Radiat Oncol Biol Phys. 1990 Dec; 19(6):1539-48.
    View in: PubMed
    Score: 0.024
  42. Radiation therapy in the treatment of cervical cancer: the University of Chicago/Michael Reese Hospital experience. J Surg Oncol. 1990 Jul; 44(3):157-65.
    View in: PubMed
    Score: 0.023
  43. Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. Head Neck. 2009 Aug; 31(8):1013-21.
    View in: PubMed
    Score: 0.022
  44. In vitro radiobiological parameters of human sarcoma cell lines. Int J Radiat Oncol Biol Phys. 1988 Oct; 15(4):937-42.
    View in: PubMed
    Score: 0.020
  45. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008 Apr 01; 26(10):1732-41.
    View in: PubMed
    Score: 0.020
  46. Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. Int J Oncol. 2006 May; 28(5):1113-9.
    View in: PubMed
    Score: 0.017
  47. Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res. 2003 May; 9(5):1689-97.
    View in: PubMed
    Score: 0.014
  48. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol. 2001 Apr 01; 19(7):1961-9.
    View in: PubMed
    Score: 0.012
  49. Equivalent racial outcome after conformal radiotherapy for prostate cancer: a single departmental experience. J Clin Oncol. 2001 Jan 01; 19(1):54-61.
    View in: PubMed
    Score: 0.012
  50. The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy: the feasibility of selective neck dissection. Arch Otolaryngol Head Neck Surg. 2000 Aug; 126(8):950-6.
    View in: PubMed
    Score: 0.012
  51. Swallowing function in patients with head and neck cancer prior to treatment. Arch Otolaryngol Head Neck Surg. 2000 Mar; 126(3):371-7.
    View in: PubMed
    Score: 0.011
  52. Volumetric visualization of head and neck CT data for treatment planning. Int J Radiat Oncol Biol Phys. 1999 Jun 01; 44(3):693-703.
    View in: PubMed
    Score: 0.011
  53. Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival. J Clin Oncol. 1998 Aug; 16(8):2715-21.
    View in: PubMed
    Score: 0.010
  54. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J Clin Oncol. 1998 Feb; 16(2):735-44.
    View in: PubMed
    Score: 0.010
  55. Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J Clin Oncol. 1996 May; 14(5):1663-71.
    View in: PubMed
    Score: 0.009
  56. Time-dose relationship for local tumor control following alternate week concomitant radiation and chemotherapy of advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 1994 Apr 30; 29(1):153-62.
    View in: PubMed
    Score: 0.008
  57. Locoregionally advanced paranasal sinus carcinoma. Favorable survival with multimodality therapy. Arch Otolaryngol Head Neck Surg. 1993 Jul; 119(7):743-6.
    View in: PubMed
    Score: 0.007
  58. Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol. 1993 Feb; 11(2):360-8.
    View in: PubMed
    Score: 0.007
  59. Perspectives on combination chemotherapy with concomitant radiotherapy for poor-prognosis head and neck cancer. Semin Oncol. 1992 Aug; 19(4 Suppl 11):47-56.
    View in: PubMed
    Score: 0.007
  60. Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer. J Natl Cancer Inst. 1992 Jun 03; 84(11):877-82.
    View in: PubMed
    Score: 0.007
  61. Measurement of bioreduction rates of cells with distinct responses to ionizing radiation and cisplatin. Biochim Biophys Acta. 1991 Jul 10; 1093(2-3):121-4.
    View in: PubMed
    Score: 0.006
  62. Radioresistant derivatives of an X-ray-sensitive CHO cell line exhibit distinct patterns of sensitivity to DNA-damaging agents. Carcinogenesis. 1990 Aug; 11(8):1265-9.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.